South Korea Nuclear Imaging Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

South Korea's nuclear imaging sector spans PET and SPECT modalities, radiopharmaceutical production and distribution, and associated diagnostic imaging services delivered through hospitals, specialty imaging centers, and diagnostic laboratories. The domestic diagnostic imaging and laboratory services market is expanding alongside, projected to reach roughly $1.81 billion across related segments by the early 2030s, reflecting sustained demand growth. The broader nuclear imaging opportunity, including the Asia-Pacific regional footprint, is valued at approximately $14.3 billion entering 2026, representing a substantial step-up from the prior year and underscoring the market's accelerating expansion.

• •Nuclear imaging encompasses PET/CT, SPECT, and related radiopharmaceutical-based diagnostic procedures targeting oncology, cardiology, and neurology
• •Domestic diagnostic labs and imaging services segment growing at roughly 7.45% CAGR toward a multi-billion-dollar market by the early 2030s
• •Broader nuclear imaging market including Asia Pacific valued at approximately $14.3 billion in 2026 with 19.06% annual growth

Demand is propelled by South Korea's aging demographic profile, which increases the incidence of age-correlated conditions such as cancer, cardiovascular disease, and neurodegenerative disorders, all primary application areas for nuclear imaging. Expanding health insurance coverage for PET and SPECT procedures, combined with government investment in precision medicine and oncology infrastructure, is lowering barriers to adoption. Technological improvements in hybrid imaging systems, shorter-lived radionuclide availability, and the emergence of theranostics, which blend diagnostic imaging with targeted radionuclide therapy, are creating new clinical and commercial pathways.

• •Aging population and rising chronic disease burden driving higher demand for oncologic and cardiac nuclear imaging procedures
• •Improved insurance reimbursement and government-backed precision medicine initiatives expanding access to PET and SPECT modalities
• •Theranostics adoption, new radionuclide pipelines, and hybrid imaging technology upgrades accelerating clinical uptake and market value

By modality, PET imaging, particularly FDG-PET and emerging gallium and copper-based tracers, commands the dominant and fastest-growing share, with SPECT remaining important for bone scans, cardiac perfusion, and thyroid imaging using technetium-99m. Application-wise, oncology represents the largest segment, followed by cardiology and neurology, with end users concentrated in tertiary hospitals and academic medical centers. Regionally, demand is heavily weighted toward major metropolitan areas where leading hospital networks and nuclear medicine departments are located, though capacity is gradually expanding into secondary and regional facilities.

• •PET imaging leads modality share, driven by FDG-PET and emerging theranostic radionuclides (gallium, copper, and fluorine-18 based); SPECT remains relevant for technetium-99m and iodine-based procedures
• •Oncology is the dominant application, with cardiology and neurology comprising the next largest clinical segments
• •Urban concentration remains high, but regional hospital expansion and government policy are broadening geographic distribution of imaging capacity

Who are the notable companies in the industry?

The market exhibits a moderately fragmented competitive structure, with a mix of large vertically integrated radiopharmaceutical producers, specialized nuclear medicine manufacturers, and regional contract manufacturing arrangements. Production is concentrated around a limited number of facilities capable of cyclotron operation and radionuclide synthesis, given the high capital requirements, regulatory barriers, and short half-life logistics inherent to the industry. Most producers pursue vertical integration across cyclotron operations, radiopharmaceutical synthesis, and radiopharmacy distribution networks, while specialty players focus on novel radionuclide development and targeted delivery platforms. Asia-Pacific regional manufacturing capacity is unevenly distributed, with advanced cyclotron infrastructure concentrated in a handful of countries including South Korea, Japan, and select Southeast Asian markets.

• •Moderately fragmented market with integrated radiopharmaceutical producers alongside specialized nuclear medicine manufacturers and contract synthesis providers
• •High capital and regulatory barriers concentrate cyclotron and radiopharmaceutical production among a limited set of vertically integrated operators
• •Asia-Pacific manufacturing capacity is concentrated in a handful of countries with advanced cyclotron infrastructure; logistics constraints from short radionuclide half-lives shape regional supply chain design

What are the recent trends and outlook?

The market is positioned for sustained double-digit growth through the end of the decade, supported by continued radiopharmaceutical innovation, expanding theranostic applications, and progressive integration of nuclear imaging into precision oncology frameworks. Digital health integration, AI-assisted image interpretation, and hybrid imaging with MRI are expected to enhance clinical utility and justify continued capital investment in next-generation equipment. Supply chain resilience for critical radionuclide feedstocks, particularly molybdenum-99 and emerging non-conventional isotopes, remains a strategic consideration for long-term market stability. The convergence of diagnostic imaging and targeted radionuclide therapy is expected to blur traditional market boundaries and drive toward a larger, integrated nuclear medicine market projected at tens of billions of dollars globally within the current decade.

• •Double-digit CAGR expected to persist through 2034, with market size potentially reaching $600-650 million domestically and far larger across the Asia-Pacific regional footprint
• •Theranostics, AI-assisted interpretation, and hybrid imaging innovation are reshaping clinical workflows and expanding the value proposition of nuclear imaging
• •Radionuclide supply chain security and domestic production capacity building are emerging as strategic policy priorities for market participants